{"pmid":32333199,"title":"Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.","text":["Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.","Pathol Oncol Res","Tsiambas, Evangelos","Papanikolaou, Vasileios","Chrysovergis, Aristeidis","Mastronikolis, Nicholas","Ragos, Vasileios","Kavantzas, Nikolaos","Lazaris, Andreas C","Kyrodimos, Efthymios","32333199"],"journal":"Pathol Oncol Res","authors":["Tsiambas, Evangelos","Papanikolaou, Vasileios","Chrysovergis, Aristeidis","Mastronikolis, Nicholas","Ragos, Vasileios","Kavantzas, Nikolaos","Lazaris, Andreas C","Kyrodimos, Efthymios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333199","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s12253-020-00810-6","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049646014465,"score":8.518259,"similar":[{"pmid":32327200,"title":"Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.","text":["Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.","Heart Lung","Omar, Michael Brandon","32327200"],"journal":"Heart Lung","authors":["Omar, Michael Brandon"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327200","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.hrtlng.2020.04.012","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664996914806915072,"score":126.76265},{"pmid":32125455,"pmcid":"PMC7079879","title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.","text":["Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.","Intensive Care Med","Zhang, Haibo","Penninger, Josef M","Li, Yimin","Zhong, Nanshan","Slutsky, Arthur S","32125455"],"journal":"Intensive Care Med","authors":["Zhang, Haibo","Penninger, Josef M","Li, Yimin","Zhong, Nanshan","Slutsky, Arthur S"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125455","week":"202010|Mar 02 - Mar 08","doi":"10.1007/s00134-020-05985-9","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664640875004690433,"score":124.47503},{"pmid":32299779,"title":"What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?","text":["What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?","Can J Cardiol","John, Thadathilankal-Jess","John, Kiran","32299779"],"journal":"Can J Cardiol","authors":["John, Thadathilankal-Jess","John, Kiran"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299779","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.cjca.2020.03.049","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664635401293266946,"score":113.73138},{"pmid":32290680,"title":"Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.","text":["Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.","Eur J Prev Cardiol","Sarzani, Riccardo","Giulietti, Federico","Pentima, Chiara Di","Giordano, Piero","Spannella, Francesco","32290680"],"journal":"Eur J Prev Cardiol","authors":["Sarzani, Riccardo","Giulietti, Federico","Pentima, Chiara Di","Giordano, Piero","Spannella, Francesco"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290680","week":"202016|Apr 13 - Apr 19","doi":"10.1177/2047487320918421","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636192766820352,"score":108.08343},{"pmid":32304146,"title":"Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.","text":["Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.","Drug Dev Res","Speth, Robert C","32304146"],"journal":"Drug Dev Res","authors":["Speth, Robert C"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304146","week":"202016|Apr 13 - Apr 19","doi":"10.1002/ddr.21672","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664632934632521728,"score":105.210434}]}